672-75-3

Basic information

• Product Name: 3-BROMO-4-FLUOROBENZOYL CHLORIDE
• Synonyms: 3-BROMO-4-FLUOROBENZOYL CHLORIDE
• CAS NO: 672-75-3
• Molecular Formula: C₇H₃BrClFO
• Molecular Weight: 237.45
• EINECS: 211-596-9
• Product Categories: Fluorine series
• Mol File: 672-75-3.mol

Chemical Properties

• Melting Point: 43-45 °C
• Boiling Point: 241.9 °C at 760 mmHg
• Flash Point: 100.1 °C
• Appearance: /
• Density: 1.742 g/cm³
• Vapor Pressure: 0.0351mmHg at 25°C
• Refractive Index: 1.561
• CAS DataBase Reference: 3-BROMO-4-FLUOROBENZOYL CHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BROMO-4-FLUOROBENZOYL CHLORIDE(672-75-3)
• EPA Substance Registry System: 3-BROMO-4-FLUOROBENZOYL CHLORIDE(672-75-3)

Safety Data

• Hazard Codes: C
• Statements: 34
• Safety Statements: 26-36/37/39
• RIDADR: 3265
• Hazardous Substances Data: 672-75-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-Bromo-4-Fluorobenzoyl chloride is used as a building block in the synthesis of various pharmaceuticals. Its unique structure allows for the creation of new drug molecules with potential therapeutic applications, contributing to the development of novel treatments for a range of medical conditions.
Used in Agrochemical Industry:
In the agrochemical sector, 3-Bromo-4-Fluorobenzoyl chloride serves as a key intermediate in the production of various agrochemicals. Its incorporation into these compounds can enhance their effectiveness in protecting crops from pests and diseases, thereby improving agricultural productivity.
Used in Organic Synthesis:
3-Bromo-4-Fluorobenzoyl chloride is utilized as a versatile reagent in organic synthesis for the preparation of a wide array of organic compounds. Its reactive nature enables it to participate in various chemical reactions, facilitating the synthesis of complex molecules for use in different industries, including the production of specialty chemicals and materials.

InChI:InChI=1/C7H3BrClFO/c8-5-3-4(7(9)11)1-2-6(5)10/h1-3H

Upstream product

• 403-43-0 4-fluorobenzoyl chloride 
• 13194-71-3 2-bromo-4-methyl-aniline; hydrochloride 
• 452-62-0 3-bromo-4-fluorotoluene 
• 1007-16-5 3-bromo-4-fluorobenzoic acid 

Downstream Products

• 1226799-75-2 3-(3-bromo-4-fluoro-benzoyl)-pyridine-2-carbonitrile 
• 1227162-78-8 2-(3-Bromo-4-fluoro-benzoyl)-6-fluoro-benzonitrile 
• 1146733-54-1 6-(3-bromo-4-fluoro-benzoyl)-3,4-dimethyl-3H-benzoxazol-2-one 
• 1146733-55-2 6-(3-bromo-4-fluoro-benzoyl)-4-methyl-3H-benzoxazol-2-one 
• 1174731-61-3 3-bromo-4-fluoro-N-(trimethylsilylmethyl)benzamide 
• 882670-70-4 3-bromo-4-fluoro-N-(2-fluoro-3-(trifluoromethyl)phenyl)benzamide 

Relevant articles and documents

Structure-Activity Relationship of Phenylpyrazolones against Trypanosoma cruzi

Chagas disease is a neglected parasitic disease caused by the parasitic protozoan Trypanosoma cruzi and currently affects around 8 million people. Previously, 2-isopropyl-5-(4-methoxy-3-(pyridin-3-yl)phenyl)-4,4-dimethyl-2,4-dihydro-3H-pyrazol-3-one (NPD-0227) was discovered to be a sub-micromolar inhibitor (pIC50=6.4) of T. cruzi. So far, SAR investigations of this scaffold have focused on the alkoxy substituent, the pyrazolone nitrogen substituent and the aromatic substituent of the core phenylpyrazolone. In this study, modifications of the phenyldihydropyrazolone scaffold are described. Variations were introduced by installing different substituents on the phenyl core, modifying the geminal dimethyl and installing various bio-isosteres of the dihydropyrazolone group. The anti T. cruzi activity of NPD-0227 could not be surpassed as the most potent compounds show pIC50 values of around 6.3. However, valuable additional SAR data for this interesting scaffold was obtained, and the data suggest that a scaffold hop is feasible as the pyrazolone moiety can be replaced by a oxazole or oxadiazole with minimal loss of activity.

Selective NK-3 receptor antagonist, preparation and application thereof

The invention provides a selective NK-3 receptor antagonist, preparation and application thereof, particularly a compound represented by the following formula (I). The compound of the invention has unexpected activity to modulate cytokines and/or interferon, and is useful in the treatment of CNS and peripheral diseases or disorders.

COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1

The present invention relates to compounds of formula I: in which Y, Y1, Y 4, Y5, Y 6, R1, R2, R3 and R4 are defined in the Summary of the Invention; capable of inhibiting the activity of BCR-ABL1 and mutants thereof. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds in the treatment of cancers.

CGRP ANTAGONISTS

The present invention relates to new CGRP-antagonists of general formula I wherein U, V, X, Y, R1, R2 and R3 are defined as stated hereinafter, the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates, the mixtures thereof and the salts thereof and the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, pharmaceutical compositions containing these compounds, their use and processes for preparing them.

INSECTICIDAL ARYLPYRROLINES

The invention relates to novel arylpyrroline compounds of formula (I) which have excellent insecticidal activity and which can thus be used as insecticides.

NOVEL BENZOFURAN DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND USES OF THESE

[From equivalent EP1710233A1] The present invention provides compounds represented by general formula (I): or pharmaceutical acceptable salts thereof, wherein R1 is hydrogen or lower alkyl; R2 is lower alkyl, halo-lower alkyl, cycloalkyl, heterocycloalkyl, aryl, aralkyl, arylalkenyl, aryloxy-lower alkyl, heteroaryl, heteroaryl-lower alkyl, etc; R3, R4, R5 and R6 are each hydrogen, halogen, cyano, lower alkyl, halo-lower alkyl, lower alkoxy, hydroxy, aryl, etc; provided that at least one of R3, R4, R5 and R6 is other than hydrogen. Compound (I) of the present invention shows a potent adenosine A2A receptor antagonistic activity, and are useful for treating or preventing a disease mediated by adenosine A2A receptors such as motor function disorders, depression, anxiety disorders, cognitive function disorders, cerebral ischemia disorders, restless legs syndrome and the like.

Substituted bromofluorobenzene derivatives and process for its manufacture

Substituted bromofluorobenzene, wherein the fluorine is in para-position and the bromine in meta-position to another substituent, is prepared by direct bromination of the corresponding fluorobenzene derivative. Bromination is advantageously carried out in the presence of a catalyst, preferably a metal or metal salt. The elementary bromine is used in an amount of 0.9 to 1.3 mols per mol of fluorobenzene derivative and the reaction temperature is between 20° and 200° C. The bromofluorobenzene derivatives are suitable for the synthesis of medicaments and plant protective agents.